Supplementary Materials to

Increased risk of fungal infection detection in women using menstrual cups vs. tampons

- Nicolas Tessandier*, Ilkay Başak Uysal#, Baptiste Elie#, Christian Selinger,
- ⁵ Claire Bernat, Vanina Boué, Sophie Grasset, Soraya Groc, Tsukushi Kamiya,
- 6 Massilva Rahmoun, Bastien Reyné, Noemi Bender, Marine Bonneau, Christelle
- Graf, Vincent Tribout, Vincent Foulongne, Jacques Ravel, Tim Waterboer,
- Christophe Hirtz, Ignacio G Bravo, Jacques Reynes, Michel Segondy, Carmen Lia
 Murall, Nathalie Boulle, Samuel Alizon*
- ¹⁰ # Equal contribution
- * Corresponding authors: nicolas.tessandier@college-de-france.fr,
- 2 samuel.alizon@cnrs.fr

December 9, 2021

14 Contents

1

2

3

13

24

25

26

27

S1 Supplementary Methods

1

6 S2 Supplementary Results

4

S1 Supplementary Methods

8 Cohort description and data curation

The participants of this analysis were 149 young women from the PAPCLEAR longitudinal clinical study which started in 2016 and was finalised in 2020. The women were aged between 18-25 years, mainly students, from the area of Montpellier (France) and their human papillomavirus status, other genital infections, immunological responses (antibodies and cytokines), behaviours were followed up for two years [1].

We selected participants who reported using tampons or cups for menstrual products, and for whom detailed cytokine profiles (see below), microbiota metabarcoding data, and antibody data at the inclusion visit were available. This amounts to N=103 women.

We assigned tampon or menstrual cup categories when a participant reported using either type of menstrual product over 75% of the time over the whole duration of the

study. There was no difference in follow-up duration between women using mostly cups or mostly tampons (Table 1).

The demographic, behavioural, and biological analyses were performed on the first two visits of the participant (V1 and V2), which were spread 4 weeks apart.

33 Biological analyses

31

32

37

38

39

40

41

Antibodies were analysed according to methods from Waterboer *et al.* [2] and already partly analysed in Murall *et al.* [3] in the context of HPV infection.

The cytokine data were obtained using MesoScale discovery (MSD) technology from vaginal secretions collected using ophthalmic sponges as described in Murall *et al.* [1] and was already analysed in the context of HPV infections by Selinger *et al.* [4]. We used the same protocol to obtain normalised values (per total protein concentration).

The microbiota profiling was performed via metabarcoding using the V3-V4 region of the 16S gene, as discussed in the study protocol [1]. The assignment of the community state type was done using the VALENCIA software package [5].

43 Statistical analysis

We used binomial regression regression models for models in Table 1, Figure 1A, and in Extended data Tables S5 and S6. For each model, we computed the odds ratios associated with each predictor along a 95% confidence interval. All analyses were performed in R (4.1.2). We used the glmulti function to conduct binomial regressions and selected the best model using the Akaike Information Criterion corrected for small sample size (AICc). We used a lowest AICc +5 interval for the most probable best models (Table S3 and S4) [6]. For clustering analysis, factor analysis of mixed data (FAMD) was used when combining both factor and numeric data (Figure 1F), and multiple correspondence analysis (MCA) was used when analysing binary data (Figure S2) [7].

53 Data availability

Table 1 and Figure 1, as well as Extended Data Tables S1, S3, S4 and Figure S2 have associated raw data. The data that support the findings of this study are available from the corresponding author upon request, and data are available in the Zenodo public repository (XXXXX).

58 Ethics

The PAPCLEAR trial is promoted by the Centre Hospitalier Universitaire de Montpellier and has been approved by the Comité de Protection des Personnes (CPP) Sud Méditerranée I on 11 May 2016 (CPP number 16 42, reference number ID RCB 2016-A00712-49); by the Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé on 12 July 2016 (reference number 16.504); and

- by the Commission Nationale Informatique et Libertés on 16 December 2016 (reference
- number MMS/ABD/AR1612278, decision number DR-2016-488). This trial was autho-
- rised by the Agence Nationale de Sécurité du Médicament et des Produits de Santé on 20
- ₆₇ July 2016 (reference 20160072000007). The ClinicalTrials.gov identifier is NCT02946346.
- 68 All participants provided written informed consent.

69 Acknowledgements

- 70 The authors thank all participants of the PAPCLEAR study and clinical staff and nurses
- 71 for their help.

72 Funding

- 73 This work was supported by the European Research Council (ERC) under the European
- Union's Horizon 2020 research and innovation programme [grant agreement No 648963
- to SA]. NT is an ANRS-MIE fellow. IBU is funded by the FHU INCH. TK is funded
- ⁷⁶ by the Fondation pour la Recherche Médicale. The sponsors had no role in the study
- design; in the collection, analysis, and interpretation of data; in the writing of the report;
- and in the decision to submit the article for publication.

79 Declaration of Competing Interest

- 80 The authors declare the following financial interests/personal relationships which may
- be considered as potential competing interests: TW serves on advisory boards for MSD
- 82 (Merck) Sharp & Dohme.

83 Contributions

- 84 NT, CLM, NBo, and SA designed the study. NT, CLM, BE, BE, TK, IGB, and SA
- designed the experiments. CB, VB, SGro, MR, and NBe performed experiments. CH,
- ₈₆ JRa, and TW contributed reagents, materials, and analysis tools. CB, VB, SGra, SGro,
- 87 MR, MB, CG, VT, VF, CLM, JRe, IGB, MSe, NBo, and SA contributed to study design,
- patient recruitment, and clinical data acquisition. NT, IBU, BE, BR, CS, TK, CLM,
- and SA performed data analyses. NT, IBU, IGB, CLM, and SA wrote the initial version
- of the manuscript. All authors approved the final version of the manuscript.

91 S2 Supplementary Results

Table S1: Key characteristics of participants included in the study. n indicates the number of individuals, p-value refers to the outcome of a Kruskal-Wallis Rank Sum Test (kruskal.test function in R), IQR is the interquartile range, SD the standard deviation.

	Tampon	Menstrual cup	p-value
n	81	22	
Follow-up duration (days, median [IQR])	301.00 [203.00, 455.00]	409.50 [238.50, 515.50]	0.165
Number of partners over the last 12 months (median [IQR])	8.00 [3.00, 15.00]	6.00 [4.00, 14.75]	0.886
Age (years, median [IQR])	21.30 (1.85)	21.95(2.50)	0.174
Age at menarchy (years, median [IQR])	13.00 [12.00, 14.00]	13.00 [12.25, 14.00]	0.665
Body Mass Index (BMI, median [IQR])	21.03 [19.61, 23.34]	21.77 [20.66, 23.41]	0.387
Antibiotics = Yes $(\%)$	5 (6.2)	2 (9.1)	0.996
Smoking = Yes (%)	31 (40.3)	5 (22.7)	0.209
Lubricant (%)	28 (35.0)	8 (36.4)	1.000
HPV positive (positive for the same HPV at the two visits) (%)	40 (49.4)	7 (31.8)	0.220
Intercourse with a regular partner (last week)	50 (61.7)	13 (59.1)	1.000
Intercourse with an occasional partner (last week)	11 (13.6)	3 (13.6)	1.000
Stress level (%)			0.081
0 (Min)	17 (21.0)	4 (18.2)	
1	35 (43.2)	7 (31.8)	
2	20 (24.7)	11 (50.0)	
3 (Max)	9 (11.1)	0 (0.0)	
Self-reported menses during the past week	44 (54.3)	15 (68.2)	0.356
Co-infected by multiple HPVs	27 (33.3)	7 (31.8)	1.000
Age at sexual debut (mean (SD))	16.40 (1.55)	16.50 (1.97)	0.792
HPV vaccinated (%)	37 (47.4)	14 (70.0)	0.121

Covariate	Data type	Values	Description	source
Number of partners over the last 12 months	Numeric	1 to 63	Number of partners over the last 12 months	Questionnaire at inclusion visit
Smoking	Binary	Yes/No	Self-reported smoking during past week	Questionnaire at inclusion visit
Intercourse with an occasional partner	Binary	Yes/No	Intercourse with an occasional partner during the past week	Questionnaire at inclusion visit
HPV vaccinated	Binary	Yes/No	Vaccinated against HPV	Questionnaire at inclusion visit
Menstrual protection	Binary	Menstrual cups/ Tampons	Questionnaire at inclusion visit	
HPV focal	Binary	Yes/No	DEIA positive for at least one HPV genotype at two consec- utive visits	Laboratory testing
Age	Numeric	21:29	Self-reported current age	Questionnaire at inclusion visit
Lubricant	Binary	Yes/No	Self-reported using sexual lubricant during past week	Questionnaire at inclusion visit
HPV positive (multiple HPV)	Binary	Yes/No	DEIA positive for at more than one HPV genotype	Laboratory testing
Antibiotics	Binary	Yes/No	Used antibiotics during past week	Questionnaire at inclusion visit
Intercourse with a regular partner	Binary	Yes/No	Self-reported intercourse with a regular partner during past week	Questionnaire at inclusion visit
Menses	Binary	Yes/No	Self-reported menses during past week	Questionnaire at inclusion visit
Stress level	Categorical	0 (Min), 1, 2, 3 (Max)	Self-reported stress level during past week	Questionnaire at inclusion visit

Table S2: Factors used in the best models selection by AICc

Model [1]	Presence in best models (#)	Presence in best models (%)	$\begin{array}{c} \text{p.value} \\ < 0.1 (\%) \end{array}$	$\begin{array}{c} \text{p.value} \\ < 0.05 (\%) \end{array}$
Smoking	68	100	100	100
Fungal infection	68	100	100	100
HPV positive (focal)	53	77.94	75	52.94
Number of partners over the last 12 months	62	91.18	75	29.41
Urinary tract infection	41	60.29	51.47	0
Menses	13	19.12	0	0
Lubricant	16	23.53	0	0
Age	15	22.06	0	0
HPV positive (multiple)	13	19.12	0	0
Intercourse with an occasional partner (last week)	10	14.71	0	0
Intercourse with a regular partner (last week)	10	14.71	0	0
HPV vaccinated	12	17.65	0	0
Stress level (1)	0	0	0	0
Stress level (2)	0	0	0	0
Stress level (3 (Max))	0	0	0	0

Table S3: Proportion of covariables presence among the 68 best models (Model 1) selected by AICc (AICc+5)

Model [2]	Presence in best models (#)	Presence in best models (%)	$\begin{array}{l} \text{p.value} \\ < 0.1(\%) \end{array}$	$\begin{array}{c} \text{p.value} \\ < 0.05 (\%) \end{array}$
Menstrual cup	111	100	100	100
Smoking	111	100	100	93.69
HPV vaccinated	91	81.98	81.98	51.35
Number of partners over the last 12 months	85	76.58	40.54	2.7
Antibiotics (last week)	105	94.59	0	0
Intercourse with a regular partner (last week)	33	29.73	0	0
Age	40	36.04	10.81	0
Intercourse with an occasional partner (last week)	28	25.23	0	0
Lubricant	37	33.33	0	0
HPV positive (multiple)	26	23.42	0	0
HPV positive (focal)	27	24.32	0	0
Menses	18	16.22	0	0
Stress level (1)	9	8.11	0	0
Stress level (2)	9	8.11	0	0
Stress level (3 (Max))	9	8.11	0	0

Table S4: Proportion of covariables presence among the 111 best models (Model 1) selected by AICc (AICc+5)

Table S5: Best model selected for covariates associated with menstrual cups usage in comparison with tampons - $First\ visit$

Response variable: MC (tampon as reference)	OR	OR SE	CI 2.5%	CI 95%	p.value	
Smoking	0.063	2.374	0.856	13.369	0.004	**
Stress level (minimum)	0.376	0.097	0.061	0.487	0.396	
Stress level (intermediate)	4.861	0.179	0.126	0.923	0.163	
Stress level (maximum)	0.000	0.020	1.001	1.080	0.994	
Fungal infection	8.474	4.220	1.856	24.103	0.077	•

^{***}p < 0.001; **p < 0.01; *p < 0.05; • p < 0.1

Table S6: Best model selected for covariates associated with menstrual cups usage in comparison with tampons - $\bf Second\ visit$

Response variable: MC (tampon as reference)	OR	OR SE	CI 2.5%	CI 95%	p.value	
Intercept	0.001	0.136	0.144	0.722	0.073	
Smoking	0.127	2.374	0.856	13.369	0.028	*
HPV infection	0.293	0.097	0.061	0.487	0.079	
Age	1.273	0.179	0.126	0.923	0.130	
Number of partners over the last 12 months	1.044	0.020	1.001	1.080	0.123	
Fungal infection	9.674	4.220	1.856	24.103	0.013	*

^{***}p < 0.001; **p < 0.01; *p < 0.05; • p < 0.1




Figure S1: Contributions of covariates to the FAMD analysis in Figure 1 A: Graph of variables vectors and their relative contribution to the FAMD analysis in Figure 1F. B and C: Percentage of contributions to dimension 1 (A) and dimension 2 (B) of the FAMD analysis in Figure 1F)




Figure S2: Multiple Correspondance Analysis of seropositivity for diverse STI antibodies

A IgG and B IgM seropositivity for a panel of STI antibodies. Antibodies included are the following. Human papillomarivus: (anti-HPV6, anti-HPV11, anti-HPV16, anti-HPV18, anti-HPV31, anti-HPV33, anti-HPV35, anti-HPV45, anti-HPV52 and anti-HPV58); Human polyomavirus: (anti-BK and anti-HPyV6), Human Herpes simplex virus: (anti-HSV2 and anti-VZV); Chlamydia trachomatis: (anti-Ct) and Mycoplasma genitalium: (anti-Mg and anti-rMg).

92 Bibliography

- 93 1. Murall, C. L. *et al.* Natural history, dynamics, and ecology of human papillomaviruses 94 in genital infections of young women: Protocol of the PAPCLEAR cohort study. *BMJ* 95 *Open* **9**, 25129 (2019).
- Waterboer, T. *et al.* Multiplex human papillomavirus serology based on in situpurified glutathione s-transferase fusion proteins. *Clin Chem* **51**, 1845–1853 (2005).
- Murall, C. L. *et al.* HPV cervical infections and serological status in vaccinated and unvaccinated women. *Vaccine* **38**, 8167–8174 (2020).
- ¹⁰⁰ 4. Selinger, C. *et al.* Cytokine response following perturbation of the cervicovaginal milieu during HPV genital infection. *Immunol. Res.* **69**, 255–263 (2021).
- 5. France, M. T. *et al.* VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. *Microbiome* **8**, 166 (2020).
- Burnham, K. & Anderson, D. Model Selection and Inference: A Practical Information-Theoretic Approach. 2, 75 (2002).
- 7. Lê, S., Josse, J. & Husson, F. FactoMineR: An R Package for Multivariate Analysis.

 Journal of Statistical Software 25, 1–18 (2008).